Papers/PMID:22824168
L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.
Nutrition journal2012The record
2 findings · 1 compound · 2 endpoints · 1 null
What it reported
How to read these marksWhat moved
1 finding
(R)-carnitine — increases body mass index
Evidence strength: limited.Finding“Patients on L-Carnitine treatment gained weight (BMI increase of 3.4% ± 1.35)whereas patients on placebo did not (BMI reduction of 1.5% ± 1.4, p < 0.018).”
Quoted verbatim from L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 4 g/day oral liquid L-carnitine
- Population
- Patients with advanced irresectable pancreatic adenocarcinoma (UICC stage IV), most receiving chemotherapy; percent change in BMI over 12 weeks
L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.2012PMID:2282416810.1186/1475-2891-11-52Permalink
What did not
1 finding
(R)-carnitine — no detected effect on hospital length of stay
Evidence strength: moderate.FindingNull result“Differences in fatigue (moderate/severe, >4 on BFI), present in 28,6% of L-Carnitine patients versus 41,7% in the placebogroup,were not statistically significant, nor was the survival benefit (median 519 ± 50d versus 399 ± 43d with placebo), and the reduction in length of hospital stay (36 ± 4d versus 41 ± 9d with placebo).”
Quoted verbatim from L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 4 g/day oral liquid L-carnitine
- Population
- Patients with advanced irresectable pancreatic adenocarcinoma (UICC stage IV), most receiving chemotherapy
L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.2012PMID:2282416810.1186/1475-2891-11-52Permalink